Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tiagabine
Drug ID BADD_D02210
Description Tiagabine is an anti-convulsive medication. It is also used in the treatment for panic disorder as are a few other anticonvulsants. Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor.
Indications and Usage For the treatment of partial seizures
Marketing Status approved; investigational
ATC Code N03AG06
DrugBank ID DB00906
KEGG ID D08588
MeSH ID D000078308
PubChem ID 60648
TTD Drug ID D0ED7U
NDC Product Code 69238-1104; 69238-1106; 69238-1105; 69238-1107
UNII Z80I64HMNP
Synonyms Tiagabine | N-(4,4-di(3-Methylthien-2-yl)but-3-enyl)nipecotic acid | Gabitril | NO 329 | NO-329 | Tiagabine Hydrochloride | (R)-(4,4-bis(3-Methyl-2-thienyl)-3-butenyl)-3-piperidinecarboxylic acid, Hydrochloride | Tiagabine, (S)-isomer | NO 328 | NO-328
Chemical Information
Molecular Formula C20H25NO2S2
CAS Registry Number 115103-54-3
SMILES CC1=C(SC=C1)C(=CCCN2CCCC(C2)C(=O)O)C3=C(C=CS3)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Musculoskeletal stiffness15.03.05.027--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Nodule08.03.05.002--Not Available
Affect lability19.04.01.001--Not Available
Haemorrhage24.07.01.002--Not Available
Paraesthesia oral07.05.05.035; 17.02.06.008--Not Available
Nuchal rigidity17.05.02.006; 15.05.04.005--Not Available
Vasodilation procedure25.03.01.001--Not Available
Muscle relaxant therapy25.16.01.001--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Urine output increased13.13.03.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Ill-defined disorder08.01.03.049--Not Available
Red blood cell abnormality01.07.02.006--Not Available
Psychotic disorder19.03.01.002--
Hyperlipidaemia14.08.03.001--
Urethritis noninfective20.07.02.002--Not Available
Cystitis noninfective20.03.02.001--
Skin mass23.07.04.014--Not Available
Anal incontinence17.05.01.021; 07.01.06.029--
Depersonalisation/derealisation disorder19.14.01.004--Not Available
Heavy menstrual bleeding21.01.03.005--Not Available
Intermenstrual bleeding21.01.01.015--Not Available
Vulvovaginal inflammation21.14.02.014--Not Available
The 9th Page    First    Pre   9    Total 9 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene